Yep, another disappointing end to what looked like a promising week of price action.
I am somewhat surprised by the stock's inability to gain any price traction. This article appeared yesterday, which supports the idea that M&A, partnerships, and strategic investments from major BPs are on the horizon.
One would think that this would add a boost to the SP of promising micro-cap biotechnology companies, yet just the opposite has happened. It does get old after awhile, the lack of any conviction regarding the SP action.
We're still waiting to hear about a trial achieving 100% enrollment. Sure would be nice to reach this on one of the trials soon.
Fingers crossed we get some kind of update next week.